Literature DB >> 33391277

Genetic Engineering of Natural Killer Cells for Enhanced Antitumor Function.

Simone Mantesso1, Dirk Geerts1, Jan Spanholtz1, Lucia Kučerová1.   

Abstract

Natural Killer (NK) cells are unique immune cells capable of efficient killing of infected and transformed cells. Indeed, NK cell-based therapies induced response against hematological malignancies in the absence of adverse toxicity in clinical trials. Nevertheless, adoptive NK cell therapies are reported to have exhibited poor outcome against many solid tumors. This can be mainly attributed to limited infiltration of NK cells into solid tumors, downregulation of target antigens on the tumor cells, or suppression by the chemokines and secreted factors present within the tumor microenvironment. Several methods for genetic engineering of NK cells were established and consistently improved over the last decade, leading to the generation of novel NK cell products with enhanced anti-tumor activity and improved tumor homing. New generations of engineered NK cells are developed to better target refractory tumors and/or to overcome inhibitory tumor microenvironment. This review summarizes recent improvements in approaches to NK cell genetic engineering and strategies implemented to enhance NK cell effector functions.
Copyright © 2020 Mantesso, Geerts, Spanholtz and Kučerová.

Entities:  

Keywords:  activating receptors; chimeric antigen receptor-natural killer cells; genetic engineering; inhibitory receptors; natural killer cells; transduction; transfection; tumor

Year:  2020        PMID: 33391277      PMCID: PMC7772419          DOI: 10.3389/fimmu.2020.607131

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  104 in total

1.  CD56(dim)CD16(+) NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases.

Authors:  B Grzywacz; N Kataria; M R Verneris
Journal:  Leukemia       Date:  2007-02       Impact factor: 11.528

2.  Generation of highly cytotoxic natural killer cells for treatment of acute myelogenous leukemia using a feeder-free, particle-based approach.

Authors:  Jeremiah L Oyer; Robert Y Igarashi; Alexander R Kulikowski; Dominic A Colosimo; Melhem M Solh; Ahmed Zakari; Yasser A Khaled; Deborah A Altomare; Alicja J Copik
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-06       Impact factor: 5.742

3.  Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population.

Authors:  K Imai; S Matsuyama; S Miyake; K Suga; K Nakachi
Journal:  Lancet       Date:  2000-11-25       Impact factor: 79.321

4.  Generation of donor natural killer cells from CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study.

Authors:  S R Yoon; Y S Lee; S H Yang; K H Ahn; Je-H Lee; Ju-H Lee; D Y Kim; Y A Kang; M Jeon; M Seol; S G Ryu; J W Chung; I Choi; K H Lee
Journal:  Bone Marrow Transplant       Date:  2009-11-02       Impact factor: 5.483

5.  Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process.

Authors:  Jan Spanholtz; Frank Preijers; Marleen Tordoir; Carel Trilsbeek; Jos Paardekooper; Theo de Witte; Nicolaas Schaap; Harry Dolstra
Journal:  PLoS One       Date:  2011-06-16       Impact factor: 3.240

6.  Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo.

Authors:  S Nagashima; R Mailliard; Y Kashii; T E Reichert; R B Herberman; P Robbins; T L Whiteside
Journal:  Blood       Date:  1998-05-15       Impact factor: 25.476

7.  The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia.

Authors:  R H Rouce; H Shaim; T Sekine; G Weber; B Ballard; S Ku; C Barese; V Murali; M-F Wu; H Liu; E J Shpall; C M Bollard; K R Rabin; K Rezvani
Journal:  Leukemia       Date:  2015-12-01       Impact factor: 11.528

8.  Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma.

Authors:  Veronika Kremer; Maarten A Ligtenberg; Rosa Zendehdel; Christina Seitz; Annet Duivenvoorden; Erik Wennerberg; Eugenia Colón; Ann-Helén Scherman-Plogell; Andreas Lundqvist
Journal:  J Immunother Cancer       Date:  2017-09-19       Impact factor: 13.751

Review 9.  Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors.

Authors:  Gaurav Nayyar; Yaya Chu; Mitchell S Cairo
Journal:  Front Oncol       Date:  2019-02-11       Impact factor: 6.244

10.  Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule.

Authors:  Cristina Bottino; Roberta Castriconi; Daniela Pende; Paola Rivera; Marina Nanni; Barbara Carnemolla; Claudia Cantoni; Jessica Grassi; Stefania Marcenaro; Nicolas Reymond; Massimo Vitale; Lorenzo Moretta; Marc Lopez; Alessandro Moretta
Journal:  J Exp Med       Date:  2003-08-11       Impact factor: 14.307

View more
  8 in total

Review 1.  NK cells in the brain: implications for brain tumor development and therapy.

Authors:  Agisilaos Balatsoukas; Filippo Rossignoli; Khalid Shah
Journal:  Trends Mol Med       Date:  2022-01-22       Impact factor: 11.951

Review 2.  Plasticity of NK cells in Cancer.

Authors:  Dillon Corvino; Ananthi Kumar; Tobias Bald
Journal:  Front Immunol       Date:  2022-05-10       Impact factor: 8.786

Review 3.  Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects.

Authors:  Reza Elahi; Amir Hossein Heidary; Kaveh Hadiloo; Abdolreza Esmaeilzadeh
Journal:  Stem Cell Rev Rep       Date:  2021-09-02       Impact factor: 6.692

4.  Boosting Natural Killer Cell Therapies in Glioblastoma Multiforme Using Supramolecular Cationic Inhibitors of Heat Shock Protein 90.

Authors:  Tanmoy Saha; Amanda A van Vliet; Chunxiao Cui; Jorge Jimenez Macias; Arpita Kulkarni; Luu Nhat Pham; Sean Lawler; Jan Spanholtz; Anna-Maria Georgoudaki; Adil Doganay Duru; Aaron Goldman
Journal:  Front Mol Biosci       Date:  2021-12-01

Review 5.  Innovative Strategies to Improve the Clinical Application of NK Cell-Based Immunotherapy.

Authors:  Mubin Tarannum; Rizwan Romee; Roman M Shapiro
Journal:  Front Immunol       Date:  2022-03-25       Impact factor: 7.561

Review 6.  iPSCs in NK Cell Manufacturing and NKEV Development.

Authors:  Nicholas Boyd-Gibbins; Peter Karagiannis; Do Won Hwang; Shin-Il Kim
Journal:  Front Immunol       Date:  2022-07-08       Impact factor: 8.786

Review 7.  Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies.

Authors:  Barbara Seliger; Ulrike Koehl
Journal:  Front Immunol       Date:  2022-08-12       Impact factor: 8.786

Review 8.  iPSC-Derived Natural Killer Cells for Cancer Immunotherapy.

Authors:  Peter Karagiannis; Shin-Il Kim
Journal:  Mol Cells       Date:  2021-08-31       Impact factor: 5.034

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.